Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features

Front Oncol. 2021 May 19:11:700599. doi: 10.3389/fonc.2021.700599. eCollection 2021.

Mingxiao Li¹, Xiaohui Ren¹, Gehong Dong², Jincheng Wang³, Haihui Jiang¹, Chuanwei Yang¹, Xuzhe Zhao¹, Qinghui Zhu¹, Yong Cui¹, Kefu Yu⁴, Song Lin^{1

5

6}

¹ Department of Neurosurgery, National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
² Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
³ Department of Radiology, Peking University Cancer Hospital, Beijing, China.
⁴ Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
⁵ Beijing Key Laboratory of Brain Tumor, Center of Brain Tumor, Institute for Brain Disorders, Beijing, China.
⁶ Department of Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.627325.].

Keywords: IDH wild-type; MGMT promoter methylation; glioblastoma; nomogram; pseudoprogression; random forest; subventricular zone.